Skip to content
Back to meeting Original
ESMO - Eur. Oncology· @myESMO · X·· 1 day agoScore70
Body

#ESMO26: The potent KRAS G12C inhibitor divarasib outperforms sotorasib and adagrasib in advanced KRAS G12C-mutated non-small cell lung cancer (#NSCLC) in the phase III Krascendo 1 #ClinicalTrial.

Read more
🔗 https://ow.ly/fm3250ZZG4k

#InsightsbyESMO #LungCancer

115 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: ESMO - Eur. Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.